American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
PLANO, Texas, July 25, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close.
Nuvectra will hold a conference call on Tuesday, August 8, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 58530044. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on August 8, 2017 through August 15, 2017. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 58530044. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, COO & CFO (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Zack Kubow (646) 536-7020 [email protected] Brian Johnston (646) 536-7028 [email protected]
